SCIB2 is the second cancer vaccine based on the ImmunoBody® technology and encodes a modified antibody engineered to express multiple epitopes from the cancer antigen NY-ESO-1. This is a well-characterised and validated cancer target, being overexpressed in several tumour types including synovial sarcomas, oesophageal, liver, gastric, prostate and lung cancers.

The Fc region of SCIB2 has also been modified using the AvidiMab® technology to generate the iSCIB2 product. This modification will enhance the Fc targeting of the iSCIB2 ImmunoBody® to dendritic cells and induce higher frequency T cell responses.

The SCIB2/iSCIB2 vaccine is under evaluation for the treatment of patients with solid tumours, including non-small cell lung cancer (NSCLC). As for the SCIB1 and iSCIB1+ vaccines, the synergistic potential of SCIB2 with a checkpoint inhibitor has been confirmed in preclinical tumour models and there is therefore a rationale for testing SCIB2 in combination with a PD-1 inhibitor in the clinic.